Cangene's VIG (Vaccinia Immune Globulin Intravenous) contract with U.S. government extended for another five years



    Listed TSX, Symbol: CNJ

    TORONTO and WINNIPEG, Aug. 16 /CNW/ - Cangene Corporation today reports
that its contract with the U.S. Centers for Disease Control and Prevention for
the supply of Vaccinia Immune Globulin Intravenous (Human) ("VIG") has been
extended for five more years. The original five-year contract was signed in
August 2002, and under that contract Cangene developed and delivered VIG
product to the U.S. Strategic National Stockpile ("SNS"). Although a supply of
product is already maintained within the SNS, the extended contract supports
licensing requirements, ongoing stability studies, further clinical testing
and development projects, and could provide for future orders.
    "This contract extension demonstrates that there is longevity associated
with these stockpiling contracts and that there is an interest in continuing
to support development and expanding our understanding of the product beyond
the initial stockpile requirement and FDA licensure," said Dr. John Langstaff,
Cangene's president and CEO.

    About VIG

    VIG is a hyperimmune product to be used in treating and preventing
certain types of severe complications that may be associated with smallpox
vaccination, and is considered to be an important component of smallpox
vaccination programs. Hyperimmunes are highly purified, specialty antibodies
made from plasma. Cangene is a world leader in developing and manufacturing
hyperimmune products; VIG, which is approved in the United States and Canada,
is part of a growing product pipeline that now includes four approved
products. Cangene manufactures VIG in its Winnipeg manufacturing facility
using a process similar to that used for WinRho(R) SDF and the Company's other
products that have been approved in Canada and/or the United States.

    About Cangene Corporation

    Cangene is one of Canada's largest and earliest biopharmaceutical
companies. It was founded in 1984 and is headquartered in Winnipeg, Manitoba.
Cangene carries out research and development in Mississauga, Ontario and in
Winnipeg. It uses patented manufacturing processes to produce plasma-derived
and recombinant therapeutic proteins. Cangene has three FDA and Health
Canada-approved products and a fourth that has been approved in Canada only.
One of its recombinant protein products has received an approvable letter from
the FDA and another has been submitted for regulatory review in Canada. In
addition, the Company has several more products in development at various
stages.
    Capitalizing on its drug manufacturing expertise, Cangene also operates a
significant contract research and manufacturing business using its Winnipeg
facilities and the resources of Baltimore, Maryland-based Chesapeake
Biological Laboratories, Inc. (a wholly owned subsidiary). An expansion in
2006 at the Winnipeg location increased the Company's capacity to fractionate
plasma to accommodate the growing manufacturing requirements. Cangene's
website, www.cangene.com, includes product and investor information, including
past news releases. Chesapeake's website is www.cblinc.com.

    Forward-looking information

    The reader should be aware that Cangene's businesses are subject to risks
and uncertainties that cannot be predicted or quantified; consequently, actual
results may differ materially from past results and those expressed or implied
by any forward-looking statements. Factors that could cause or contribute to
such risks or uncertainties include, but are not limited to: the regulatory
environment including the difficulty of predicting regulatory outcomes;
changes in the value of the Canadian dollar; the Company's reliance on a small
number of customers including government organizations; the demand for new
products and the impact of competitive products, service and pricing;
availability and cost of raw materials, especially the cost, availability and
antibody concentration in plasma; fluctuations in operating results;
government policies or actions; progress and cost of clinical trials; reliance
on key strategic relationships; costs and possible development delays
resulting from use of legal, regulatory or legislative strategies by the
Company's competitors; uncertainty related to intellectual property protection
and potential cost associated with its defence; the Company's exposure to
lawsuits, and other matters beyond control of management.
    Risks and uncertainties are discussed more extensively in the MD&A
section of the Company's most recent annual report and annual information
form, which are available on the Company's website or on SEDAR at
www.sedar.com. Scientific information that relates to unapproved products or
unapproved uses of products is preliminary and investigative. No conclusions
can or should be drawn regarding the safety or efficacy of such products. Only
regulatory authorities can determine whether products are safe and effective
for the uses being investigated. Healthcare professionals are directed to
refer to approved labelling for products and not rely on information presented
in news releases.
    The cautionary statements referred to above should be considered in
connection with all written or oral statements, especially forward-looking
statements, that are made by the Company or by persons acting on its behalf
and in conjunction with its periodic filings with Securities Commissions,
including those contained in the Company's news releases and most recently
filed annual information form. Forward-looking statements can be identified by
the use of words such as "expects", "plans", "will", "believes", "estimates",
"intends", "may", "bodes" and other words of similar meaning (including
negative and grammatical variations). Should known or unknown risks or
uncertainties materialize, or should management's assumptions prove
inaccurate, actual results could vary materially from those anticipated. The
Company undertakes no obligation to publicly make or update any
forward-looking statements, except as required by applicable law.


    %SEDAR: 00002351E




For further information:

For further information: John McMillan at (204) 275-4310 or by email at
jmcmillan@cangene.com

Organization Profile

Cangene Corporation

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890